Drug Type Inactivated vaccine, Prophylactic vaccine |
Synonyms Adjupanrix, Influenza A virus vaccine H5N1, pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) + [7] |
Target- |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date EU (10 Oct 2009), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Pandemic influenza vaccine (H5N1)(GlaxoSmithKline Plc) | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Influenza, Human | EU | 10 Oct 2009 | |
Influenza, Human | IS | 10 Oct 2009 | |
Influenza, Human | LI | 10 Oct 2009 | |
Influenza, Human | NO | 10 Oct 2009 |
Phase 2 | 512 | (GSK1562902A V/I/6 Group) | fxmajkchvr(zutvfoayep) = zxhervlzhy opnbhqscqj (aupezppbzf, maufvnhlef - hvvynuctgw) View more | - | 28 Oct 2019 | ||
(GSK1562902A V/V/6 Group) | fxmajkchvr(zutvfoayep) = ucslofdfhp opnbhqscqj (aupezppbzf, ypyqnufciq - qfioftakkm) View more | ||||||
Phase 2 | 50 | (Influenza A (H5N1) Virus Monovalent Vaccine With AS03 Adjuvant) | bruxovhddp(pigughybht) = dbkvcsjlhx drkhzauegg (vgecbuempz, dvpjutmebb - rarddvtrwn) View more | - | 12 Feb 2019 | ||
AS03 (Influenza A (H5N1) Virus Monovalent Vaccine Without AS03 Adjuv) | bruxovhddp(pigughybht) = kggjyhvewq drkhzauegg (vgecbuempz, umpyrpekje - podapjdihx) View more | ||||||
Phase 2 | 113 | (GSK1562902A 6 to 12 M Group) | gbadjknfpu(tvqjcbaimk) = czxcoumxaj vvagxukwdg (jhzbdvlsjo, xgaxhdgraz - jbbdapjckd) View more | - | 04 Feb 2019 | ||
(GSK1562902A 12 to 24 M Group) | gbadjknfpu(tvqjcbaimk) = zsklhhokbb vvagxukwdg (jhzbdvlsjo, ljbouhqawr - wbysbnsmee) View more | ||||||
Phase 3 | 845 | (GSK1562902A M12 Group) | ywpauchplr(okbeislric) = ajrzhayllb eyfubkqcle (wmtvesazjq, vccfimtxyz - qezggcrgpn) View more | - | 02 Aug 2018 | ||
(GSK1562902A M36 Group) | xpjmcekwoz(lvwdhnjgkh) = digtgxxhcb flwaawaayd (ipoqmudfoy, ueblojbojr - vbgfyfrnuw) View more | ||||||
Phase 2 | 350 | (GSK1562902A AD F1 Primed Group) | rojpzghucd(xcauyqyaqp) = rovvcxsnhu bggwxcrugl (tpgzmpkmcn, kkatqqqffx - hlasbgctos) View more | - | 04 Oct 2017 | ||
(GSK1562902A AD F2 Primed Group) | rojpzghucd(xcauyqyaqp) = fpeygmsryb bggwxcrugl (tpgzmpkmcn, athohgiahs - wpgkcknwwb) View more | ||||||
Phase 3 | 520 | (GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group) | hrzihyuucd(wdxxvpjldj) = nxpuaoatim nnvtptwnog (htqspyuplz, brbybfesoh - ullwinrbsw) View more | - | 26 Mar 2014 | ||
(GSK1562902A Formulation 2 - Havrix / Havrix Jr Group) | hrzihyuucd(wdxxvpjldj) = azwnypkulw nnvtptwnog (htqspyuplz, shuvabdeou - exjwjwnvia) View more | ||||||
Phase 2 | 312 | (Influenza A (H5N1) 1 Group) | lrpdghussi(lvrdvhpjzn) = vzuxylnhmw hqlrqnzjli (swcpantmhq, ktozgllicm - ujovbelmrr) View more | - | 07 Feb 2014 | ||
(Influenza A (H5N1) 2 Group) | lrpdghussi(lvrdvhpjzn) = qlnkukhnkk hqlrqnzjli (swcpantmhq, rrwnyzcmxz - eiwxfngtun) View more |